Aditxt, Inc. Accounts Receivable, Allowance for Credit Loss, Current
Aditxt, Inc. (ADTX) had Accounts Receivable, Allowance for Credit Loss, Current of $0 as of 2026-03-31, per its 10-Q filed 2026-05-20.
Financial Statements › Balance Sheet › Assets › Assets, Current › Accounts Receivable, after Allowance for Credit Loss, Current
us-gaap:AllowanceForDoubtfulAccountsReceivableCurrent · last filed 2026-05-20
- 2026-03-31: Accounts Receivable, Allowance for Credit Loss, Current $0.00.
- 2025-12-31: Accounts Receivable, Allowance for Credit Loss, Current $0.00.
- 2025-09-30: Accounts Receivable, Allowance for Credit Loss, Current $77.91K.
- 2025-06-30: Accounts Receivable, Allowance for Credit Loss, Current $77.91K.
| Period end | Accounts Receivable, Allowance for Credit Loss, Current |
|---|---|
| 2026-03-31 | $0.00 10-Q · filed 2026-05-20 |
| 2025-12-31 | $0.00 10-Q · filed 2026-05-20 |
| 2025-09-30 | $77.91K 10-Q · filed 2025-11-18 |
| 2025-06-30 | $77.91K 10-Q · filed 2025-08-14 |
| 2025-03-31 | $77.91K 10-Q · filed 2025-05-15 |
| 2024-12-31 | $78.15K 10-K · filed 2026-03-31 |
| 2024-09-30 | $49.96K 10-Q · filed 2024-11-18 |
| 2024-06-30 | $49.96K 10-Q · filed 2024-08-19 |
| 2024-03-31 | $0.00 10-Q · filed 2024-05-20 |
| 2023-12-31 | $0.00 10-K · filed 2025-03-31 |
| 2023-09-30 | $0.00 10-Q · filed 2023-11-14 |
| 2022-12-31 | $18.63K 10-K · filed 2024-04-16 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Rafael Holdings, Inc. (RFL) | United States | $0.000B | -0.00 |
| CDT Equity Inc. (CDT) | United States | $0.000B | -0.01 |
| Protagenic Therapeutics, Inc.\new (PTIX) | United States | $0.001B | |
| Decoy Therapeutics Inc. (DCOY) | United States | $0.002B | -0.27 |
| Nexentis Technologies Inc. (NXTS) | $0.002B | ||
| ORAGENICS INC (OGEN) | United States | $0.002B | |
| JUPITER NEUROSCIENCES, INC. (JUNS) | United States | $0.002B | -0.02 |
| BioXcel Therapeutics, Inc. (BTAI) | United States | $0.002B | |
| ZyVersa Therapeutics, Inc. (ZVSA) | United States | $0.002B | |
| Matinas BioPharma Holdings, Inc. (MTNB) | United States | $0.003B |